riluzole has been researched along with Injuries, Spinal Cord in 53 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Immediate treatment of spinal root avulsion injuries with minocycline or riluzole prevents the onset of evoked pain hypersensitivity by reducing microglial cell activation." | 7.80 | The effects of minocycline or riluzole treatment on spinal root avulsion-induced pain in adult rats. ( Carlstedt, T; Chew, DJ; Shortland, PJ, 2014) |
| "Riluzole has a neuroprotective effect in a rat model of spinal cord injury/reperfusion when administered up to 4h post-injury, a clinically relevant therapeutic time window." | 5.40 | Riluzole improves outcome following ischemia-reperfusion injury to the spinal cord by preventing delayed paraplegia. ( Fehlings, MG; Satkunendrarajah, K; Wu, Y, 2014) |
| "Compared with the other groups, a statistically significant difference with regard to better results for necrosis, inflammation, and apoptosis was observed in the riluzole only and combination groups." | 3.85 | Combined and individual use of pancaspase inhibitor Q-VD-OPh and NMDA receptor antagonist riluzole in experimental spinal cord injury. ( Altunrende, ME; Aydoseli, A; Can, H; Dolgun, M; Göker, B; Gömleksiz, C; Sencer, A, 2017) |
| "Immediate treatment of spinal root avulsion injuries with minocycline or riluzole prevents the onset of evoked pain hypersensitivity by reducing microglial cell activation." | 3.80 | The effects of minocycline or riluzole treatment on spinal root avulsion-induced pain in adult rats. ( Carlstedt, T; Chew, DJ; Shortland, PJ, 2014) |
| "Riluzole is a sodium-glutamate antagonist that attenuates neurodegeneration in amyotrophic lateral sclerosis (ALS)." | 3.30 | Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial. ( Aarabi, B; Ahmad, FU; Arnold, PM; Ball, J; Brodke, DS; Brooks, NP; Chow, DS; Fehlings, MG; Freeman, BJC; Guest, JD; Harrop, JS; Kopjar, B; Kurpad, SN; Moghaddamjou, A; Nassr, A; Ray, WZ; Schmitt, KM; Schuster, JM; Stanford, R; Toups, EG; Wilson, J; Wilson, JR; Yee, A, 2023) |
| " A 1-compartment with first-order elimination population pharmacokinetic model for riluzole incorporating time-dependent clearance and volume of distribution was developed from combined data of the phase 1 and the ongoing phase 2/3 trials." | 3.01 | Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent. ( Aarabi, B; Boakye, M; Chow, DS; Fehlings, MG; Frankowski, RF; Grossman, RG; Guest, JD; Harrop, JS; Johnson, MM; Nguyen, A; Sarkar, M; Schmitt, KM; Shaffrey, CI; Teng, YA; Toups, EG; Wu, L, 2021) |
| "Riluzole is a sodium channel-blocking agent used in treating amyotrophic lateral sclerosis." | 2.82 | Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial. ( Chow, DS; Fehlings, MG; Grossman, RG; Kopjar, B; Nagoshi, N; Nakashima, H, 2016) |
| "Riluzole plasma levels were significantly higher on day 3 than on day 14, resulting from a lower clearance and a smaller volume of distribution on day 3." | 2.79 | A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. ( Aarabi, B; Boakye, M; Burau, KD; Chow, DS; Fehlings, MG; Frankowski, RF; Grossman, RG; Guest, JD; Harkema, SJ; Harrop, JS; Johnson, MM; Shaffrey, CI; Tator, C; Teng, A; Toups, EG; Wilson, JR, 2014) |
| " The pharmacokinetic measures studied were the peak concentration (C(max)), trough concentration (C(min)), systemic exposure (AUC(0-12)), clearance (CL/F), and volume of distribution (V_F) normalized by the bioavailability (F)." | 2.77 | Pharmacology of riluzole in acute spinal cord injury. ( Aarabi, B; Boakye, M; Chow, DS; Fehlings, MG; Frankowski, RF; Grossman, RG; Harrop, JS; Johnson, MM; Shaffrey, CI; Teng, Y; Toups, EG, 2012) |
| "Riluzole was associated with improved outcomes in the inclined plane test and the tissue preservation area." | 2.61 | Riluzole promotes neurological function recovery and inhibits damage extension in rats following spinal cord injury: a meta-analysis and systematic review. ( Chen, XQ; Cui, XJ; Song, YJ; Tian, ZR; Wang, YJ; Yao, M; Ye, J; Yi, NX; Zhou, LY, 2019) |
| " Key findings from pharmacological studies included riluzole dose-dependent effects on glutamate uptake and its modified bioavailability after SCI in both animal and clinical models." | 2.61 | Efficacy of riluzole in the treatment of spinal cord injury: a systematic review of the literature. ( Pham, MH; Srinivas, S; Wali, AR, 2019) |
| "Riluzole is a benzothiazole anticonvulsant with neuroprotective effects." | 2.52 | Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside. ( Fehlings, MG; Nagoshi, N; Nakashima, H, 2015) |
| "Riluzole is a benzothiazole anticonvulsant used in the treatment of patients with amyotrophic lateral sclerosis and it is being investigated for clinical use in patients with spinal cord injury." | 1.51 | Pharmacokinetics of Riluzole in Beagle Dogs. ( Antunes, NJ; Corrêa, SVM; da Costa, RC; de Freitas, NL; De Nucci, G; Juni, LT; Mendes, GD; Moreno, RA; Perdigão, APL; Rojas-Moscoso, J, 2019) |
| "Riluzole treatment is more effective when provided before injury." | 1.48 | Effect of Riluzole on Spinal Cord Regeneration with Hemisection Method Before Injury. ( Al-Beyati, ESM; Bahadir, B; Caglar, YS; Cansiz, C; Demirel, A; Dogan, I; Eroglu, U; Huseynov, R; Kilinc, MC; Ozgural, O, 2018) |
| "Riluzole treatment induced significant axonal preservation, as well as serotonergic fiber sparing, caudally to the injury epicenter." | 1.43 | Combining neuroprotective agents: effect of riluzole and magnesium in a rat model of thoracic spinal cord injury. ( Gomes, ED; Lima, R; Oliveira, EP; Salgado, AJ; Silva, CJ; Silva, NA; Sousa, N; Vasconcelos, NL, 2016) |
| "Riluzole has a neuroprotective effect in a rat model of spinal cord injury/reperfusion when administered up to 4h post-injury, a clinically relevant therapeutic time window." | 1.40 | Riluzole improves outcome following ischemia-reperfusion injury to the spinal cord by preventing delayed paraplegia. ( Fehlings, MG; Satkunendrarajah, K; Wu, Y, 2014) |
| " We found that licofelone both reduced Pgp expression and enhanced riluzole bioavailability within the lesion site at 72 h post-SCI." | 1.39 | The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord. ( Dulin, JN; Grill, RJ; Moore, ML, 2013) |
| "Riluzole is a pleotropic drug that blocks "persistent sodium currents" in neurons, but in SCI, its molecular mechanism of action is uncertain." | 1.38 | Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury. ( Gerzanich, V; Ivanov, A; Ivanova, S; Keledjian, K; Simard, JM; Tsymbalyuk, O, 2012) |
| "Riluzole treatment starting at 14 and 16 days after injury resulted in significantly lower number of reinnervating motoneurons (67+/-4 and 52+/-3 S." | 1.34 | Delayed riluzole treatment is able to rescue injured rat spinal motoneurons. ( Nógrádi, A; Pintér, S; Szabó, A; Vrbová, G, 2007) |
| "Riluzole treatment was found to improve mitochondrial function, and enhance glutamate and glucose uptake." | 1.31 | Riluzole improves measures of oxidative stress following traumatic spinal cord injury. ( Azbill, RD; Mu, X; Springer, JE, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.77) | 18.2507 |
| 2000's | 8 (15.09) | 29.6817 |
| 2010's | 34 (64.15) | 24.3611 |
| 2020's | 9 (16.98) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, Q | 3 |
| Zhang, W | 6 |
| Yuan, S | 1 |
| Zhang, Y | 6 |
| Chen, X | 3 |
| Zang, L | 1 |
| Xu, S | 2 |
| Liu, T | 1 |
| Cotinat, M | 1 |
| Boquet, I | 1 |
| Ursino, M | 1 |
| Brocard, C | 2 |
| Jouve, E | 1 |
| Alberti, C | 1 |
| Bensoussan, L | 1 |
| Viton, JM | 1 |
| Brocard, F | 2 |
| Blin, O | 1 |
| Chow, DS | 8 |
| Nguyen, A | 2 |
| Park, J | 1 |
| Wu, L | 2 |
| Toups, EG | 9 |
| Harrop, JS | 8 |
| Guest, JD | 6 |
| Schmitt, KM | 3 |
| Aarabi, B | 7 |
| Fehlings, MG | 19 |
| Boakye, M | 4 |
| Grossman, RG | 9 |
| Moghaddamjou, A | 1 |
| Stanford, R | 1 |
| Ball, J | 1 |
| Freeman, BJC | 1 |
| Arnold, PM | 1 |
| Kurpad, SN | 1 |
| Schuster, JM | 1 |
| Nassr, A | 1 |
| Wilson, JR | 5 |
| Brodke, DS | 1 |
| Ahmad, FU | 1 |
| Yee, A | 1 |
| Ray, WZ | 1 |
| Brooks, NP | 1 |
| Wilson, J | 1 |
| Kopjar, B | 2 |
| Neal, CJ | 1 |
| Hejrati, N | 1 |
| Liu, Y | 1 |
| Guan, Y | 1 |
| Teng, YA | 1 |
| Sarkar, M | 2 |
| Johnson, MM | 3 |
| Shaffrey, CI | 4 |
| Frankowski, RF | 5 |
| Kazim, SF | 1 |
| Bowers, CA | 1 |
| Cole, CD | 1 |
| Varela, S | 1 |
| Karimov, Z | 1 |
| Martinez, E | 1 |
| Ogulnick, JV | 1 |
| Schmidt, MH | 1 |
| Can, H | 1 |
| Aydoseli, A | 1 |
| Gömleksiz, C | 1 |
| Göker, B | 1 |
| Altunrende, ME | 1 |
| Dolgun, M | 1 |
| Sencer, A | 1 |
| Martins, BC | 1 |
| Torres, BBJ | 1 |
| de Oliveira, KM | 1 |
| Lavor, MS | 1 |
| Osório, CM | 1 |
| Fukushima, FB | 1 |
| Rosado, IR | 1 |
| de Melo, EG | 1 |
| Sámano, C | 2 |
| Nistri, A | 2 |
| Shimizu, EN | 1 |
| Seifert, JL | 1 |
| Johnson, KJ | 1 |
| Romero-Ortega, MI | 1 |
| Caglar, YS | 1 |
| Demirel, A | 1 |
| Dogan, I | 1 |
| Huseynov, R | 1 |
| Eroglu, U | 1 |
| Ozgural, O | 1 |
| Cansiz, C | 1 |
| Bahadir, B | 1 |
| Kilinc, MC | 1 |
| Al-Beyati, ESM | 1 |
| Perdigão, APL | 1 |
| Antunes, NJ | 1 |
| Juni, LT | 1 |
| de Freitas, NL | 1 |
| Rojas-Moscoso, J | 1 |
| Corrêa, SVM | 1 |
| da Costa, RC | 1 |
| Moreno, RA | 1 |
| Mendes, GD | 1 |
| De Nucci, G | 1 |
| Zhou, LY | 1 |
| Tian, ZR | 1 |
| Yao, M | 1 |
| Chen, XQ | 1 |
| Song, YJ | 1 |
| Ye, J | 1 |
| Yi, NX | 1 |
| Cui, XJ | 1 |
| Wang, YJ | 1 |
| Srinivas, S | 1 |
| Wali, AR | 1 |
| Pham, MH | 1 |
| Chapela, D | 1 |
| Sousa, S | 1 |
| Martins, I | 1 |
| Cristóvão, AM | 1 |
| Pinto, P | 1 |
| Corte-Real, S | 1 |
| Saúde, L | 1 |
| Wu, Y | 2 |
| Satkunendrarajah, K | 3 |
| Teng, Y | 2 |
| Buttigieg, J | 1 |
| Burau, KD | 3 |
| Tator, C | 1 |
| Teng, A | 1 |
| Harkema, SJ | 2 |
| Chew, DJ | 1 |
| Carlstedt, T | 1 |
| Shortland, PJ | 2 |
| Nagoshi, N | 2 |
| Nakashima, H | 2 |
| Hosier, H | 1 |
| Peterson, D | 1 |
| Tsymbalyuk, O | 2 |
| Keledjian, K | 2 |
| Smith, BR | 1 |
| Ivanova, S | 2 |
| Gerzanich, V | 2 |
| Popovich, PG | 1 |
| Simard, JM | 2 |
| Nassiri, F | 1 |
| Karadimas, SK | 1 |
| Lip, A | 1 |
| Yao, G | 1 |
| Plantier, V | 1 |
| Boulenguez, P | 1 |
| Liabeuf, S | 1 |
| Bouhadfane, M | 1 |
| Viallat-Lieutaud, A | 1 |
| Vinay, L | 1 |
| Vasconcelos, NL | 1 |
| Gomes, ED | 1 |
| Oliveira, EP | 1 |
| Silva, CJ | 1 |
| Lima, R | 1 |
| Sousa, N | 1 |
| Salgado, AJ | 1 |
| Silva, NA | 1 |
| Thibault-Halman, G | 1 |
| Rivers, CS | 1 |
| Bailey, CS | 1 |
| Tsai, EC | 1 |
| Drew, B | 1 |
| Noonan, VK | 1 |
| Dvorak, MF | 1 |
| Kuerban, D | 1 |
| Kwon, BK | 1 |
| Christie, SD | 1 |
| Johnson, CD | 1 |
| D'Amato, AR | 1 |
| Gilbert, RJ | 1 |
| Kitzman, PH | 1 |
| Hama, A | 1 |
| Sagen, J | 1 |
| Cadotte, DW | 1 |
| Theiss, RD | 1 |
| Hornby, TG | 1 |
| Rymer, WZ | 1 |
| Schmit, BD | 1 |
| Ivanov, A | 1 |
| Nasrabady, SE | 1 |
| Dulin, JN | 1 |
| Moore, ML | 1 |
| Grill, RJ | 1 |
| Howley, S | 1 |
| Tator, CH | 2 |
| Johnson, MW | 1 |
| Hashimoto, R | 1 |
| Raich, A | 1 |
| Norvell, D | 1 |
| Guest, J | 1 |
| Forgione, N | 1 |
| Schwartz, G | 2 |
| Nógrádi, A | 1 |
| Szabó, A | 1 |
| Pintér, S | 1 |
| Vrbová, G | 1 |
| Leinster, VH | 1 |
| White, W | 1 |
| Robson, LG | 1 |
| Ates, O | 1 |
| Cayli, SR | 1 |
| Gurses, I | 1 |
| Turkoz, Y | 1 |
| Tarim, O | 1 |
| Cakir, CO | 1 |
| Kocak, A | 1 |
| Springer, JE | 3 |
| Azbill, RD | 3 |
| Kennedy, SE | 1 |
| George, J | 1 |
| Geddes, JW | 1 |
| Wahl, F | 1 |
| Stutzmann, JM | 1 |
| Mu, X | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Feasibility of Virtual Reality-Based Activities for Upper Limb Rehabilitation of People With Acute/Sub-Acute Tetraplegia[NCT06154122] | 24 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
| A Multi-Center, Randomized, Placebo Controlled, Double-Blinded, Trial of Efficacy and Safety of Riluzole in Acute Spinal Cord Injury[NCT01597518] | Phase 2/Phase 3 | 193 participants (Actual) | Interventional | 2013-10-31 | Terminated (stopped due to Enrollment challenges/ slow enrollment.) | ||
| Safety and Pharmacokinetics of Riluzole in Patients With Traumatic Acute Spinal Cord Injury[NCT00876889] | 36 participants (Actual) | Observational | 2010-04-30 | Completed | |||
| Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma[NCT00739154] | 200 participants (Anticipated) | Observational | 2008-11-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for riluzole and Injuries, Spinal Cord
| Article | Year |
|---|---|
Corticospinal Motor Circuit Plasticity After Spinal Cord Injury: Harnessing Neuroplasticity to Improve Functional Outcomes.
Topics: Animals; Brain-Computer Interfaces; Combined Modality Therapy; Electric Stimulation Therapy; Humans; | 2021 |
Mechanism of Neuroprotection Against Experimental Spinal Cord Injury by Riluzole or Methylprednisolone.
Topics: Animals; Anti-Inflammatory Agents; Humans; Methylprednisolone; Neuroprotection; Neuroprotective Agen | 2019 |
Riluzole promotes neurological function recovery and inhibits damage extension in rats following spinal cord injury: a meta-analysis and systematic review.
Topics: Animals; Neuroprotective Agents; Rats; Recovery of Function; Riluzole; Spinal Cord; Spinal Cord Inju | 2019 |
Efficacy of riluzole in the treatment of spinal cord injury: a systematic review of the literature.
Topics: Adolescent; Adult; Aged; Animals; Biological Availability; Clinical Trials as Topic; Drug Evaluation | 2019 |
Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside.
Topics: Adult; Amyotrophic Lateral Sclerosis; Animals; Clinical Trials as Topic; Humans; Neuroprotective Age | 2015 |
Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside.
Topics: Adult; Amyotrophic Lateral Sclerosis; Animals; Clinical Trials as Topic; Humans; Neuroprotective Age | 2015 |
Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside.
Topics: Adult; Amyotrophic Lateral Sclerosis; Animals; Clinical Trials as Topic; Humans; Neuroprotective Age | 2015 |
Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside.
Topics: Adult; Amyotrophic Lateral Sclerosis; Animals; Clinical Trials as Topic; Humans; Neuroprotective Age | 2015 |
Spinal cord injury: a systematic review of current treatment options.
Topics: Animals; Decompression, Surgical; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Inhib | 2011 |
Translational potential of preclinical trials of neuroprotection through pharmacotherapy for spinal cord injury.
Topics: Animals; Disease Models, Animal; Glyburide; Humans; Magnesium Sulfate; Minocycline; Neuroprotective | 2012 |
Emerging therapies for acute traumatic spinal cord injury.
Topics: ADP Ribose Transferases; Botulinum Toxins; Cell Transplantation; Decompression, Surgical; Hemodynami | 2013 |
Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole.
Topics: Animals; Humans; Neuroprotective Agents; Riluzole; Sodium Channel Blockers; Spinal Cord Injuries | 2002 |
9 trials available for riluzole and Injuries, Spinal Cord
| Article | Year |
|---|---|
Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial.
Topics: Adult; Bayes Theorem; Clinical Trials, Phase I as Topic; Double-Blind Method; Humans; Multicenter St | 2023 |
Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Pha
Topics: Amyotrophic Lateral Sclerosis; Cervical Cord; Humans; Male; Middle Aged; Neck Injuries; Neuroprotect | 2023 |
Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial.
Topics: COVID-19; Double-Blind Method; Humans; Neuroprotective Agents; Pandemics; Prospective Studies; Riluz | 2023 |
Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent.
Topics: Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Half-Life; | 2021 |
A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury.
Topics: Adolescent; Adult; Aged; Cervical Vertebrae; Female; Humans; Male; Middle Aged; Neuroprotective Agen | 2014 |
Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Female; Follow-Up Studies; Humans; Male | 2016 |
Riluzole decreases flexion withdrawal reflex but not voluntary ankle torque in human chronic spinal cord injury.
Topics: Adult; Analysis of Variance; Ankle; Double-Blind Method; Electric Stimulation; Electromyography; Fem | 2011 |
Pharmacology of riluzole in acute spinal cord injury.
Topics: Adolescent; Adult; Aged; Biological Availability; Chromatography, High Pressure Liquid; Female; Huma | 2012 |
Pharmacology of riluzole in acute spinal cord injury.
Topics: Adolescent; Adult; Aged; Biological Availability; Chromatography, High Pressure Liquid; Female; Huma | 2012 |
Pharmacology of riluzole in acute spinal cord injury.
Topics: Adolescent; Adult; Aged; Biological Availability; Chromatography, High Pressure Liquid; Female; Huma | 2012 |
Pharmacology of riluzole in acute spinal cord injury.
Topics: Adolescent; Adult; Aged; Biological Availability; Chromatography, High Pressure Liquid; Female; Huma | 2012 |
Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.
Topics: Humans; Neuroprotective Agents; Research Design; Riluzole; Spinal Cord Injuries | 2012 |
Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.
Topics: Humans; Neuroprotective Agents; Research Design; Riluzole; Spinal Cord Injuries | 2012 |
Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.
Topics: Humans; Neuroprotective Agents; Research Design; Riluzole; Spinal Cord Injuries | 2012 |
Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.
Topics: Humans; Neuroprotective Agents; Research Design; Riluzole; Spinal Cord Injuries | 2012 |
35 other studies available for riluzole and Injuries, Spinal Cord
| Article | Year |
|---|---|
A Single Administration of Riluzole Applied Acutely After Spinal Cord Injury Attenuates Pro-inflammatory Activity and Improves Long-Term Functional Recovery in Rats.
Topics: Animals; Inflammation; Neuroprotective Agents; Rats; Rats, Wistar; Recovery of Function; Riluzole; S | 2022 |
Riluzole Promotes Neurite Growth in Rats after Spinal Cord Injury through the GSK-3β/CRMP-2 Pathway.
Topics: Animals; Glycogen Synthase Kinase 3 beta; Humans; Intercellular Signaling Peptides and Proteins; Ner | 2022 |
An Introduction to the North American Clinical Trials Network for Spinal Cord Injury Special Edition: Reflections on Accomplishments and a Look to the Future.
Topics: Canada; Clinical Trials as Topic; Humans; Recovery of Function; Riluzole; Spinal Cord Injuries | 2023 |
Riluzole improves functional recovery after acute spinal cord injury in rats and may be associated with changes in spinal microglia/macrophages polarization.
Topics: Animals; Cell Polarity; Female; Macrophages; Microglia; Neuroprotective Agents; Rats; Rats, Wistar; | 2020 |
UPLC-MS/MS assay of riluzole in human plasma and cerebrospinal fluid (CSF): Application in samples from spinal cord injured patients.
Topics: Acetates; Biological Assay; Calibration; Cerebrospinal Fluid; Chromatography, High Pressure Liquid; | 2017 |
Combined and individual use of pancaspase inhibitor Q-VD-OPh and NMDA receptor antagonist riluzole in experimental spinal cord injury.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Disease Models, Animal; Male; Necrosis; Neuropr | 2017 |
Association of riluzole and dantrolene improves significant recovery after acute spinal cord injury in rats.
Topics: Animals; Apoptosis; Dantrolene; Drug Combinations; Drug Synergism; Male; Neuroprotective Agents; Rat | 2018 |
Prophylactic Riluzole Attenuates Oxidative Stress Damage in Spinal Cord Distraction.
Topics: Animals; Female; Motor Neurons; Neuroprotective Agents; Oxidative Stress; Rats; Rats, Long-Evans; Ri | 2018 |
Effect of Riluzole on Spinal Cord Regeneration with Hemisection Method Before Injury.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Lam | 2018 |
Pharmacokinetics of Riluzole in Beagle Dogs.
Topics: Administration, Oral; Animals; Area Under Curve; Chromatography, Liquid; Dogs; Female; Male; Plasma; | 2019 |
A zebrafish drug screening platform boosts the discovery of novel therapeutics for spinal cord injury in mammals.
Topics: Animals; Cycloserine; Disease Models, Animal; Drug Discovery; Drug Evaluation, Preclinical; Female; | 2019 |
Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury.
Topics: Animals; Cervical Vertebrae; Disease Models, Animal; Drug Evaluation, Preclinical; Evoked Potentials | 2013 |
Riluzole improves outcome following ischemia-reperfusion injury to the spinal cord by preventing delayed paraplegia.
Topics: Animals; Female; Neuroprotective Agents; Paraplegia; Rats; Reperfusion Injury; Riluzole; Spinal Cord | 2014 |
The effects of minocycline or riluzole treatment on spinal root avulsion-induced pain in adult rats.
Topics: Animals; Disease Models, Animal; Functional Laterality; Hyperalgesia; Male; Minocycline; Neurons; Ne | 2014 |
A Direct Comparison of Three Clinically Relevant Treatments in a Rat Model of Cervical Spinal Cord Injury.
Topics: Animals; Behavior, Animal; Cervical Cord; Disease Models, Animal; Female; Glyburide; Hypoglycemic Ag | 2015 |
Riluzole promotes motor and respiratory recovery associated with enhanced neuronal survival and function following high cervical spinal hemisection.
Topics: Animals; Cell Survival; Cervical Cord; Male; Motor Neurons; Neuronal Plasticity; Neurons; Neuroprote | 2016 |
Cleavage of Na(+) channels by calpain increases persistent Na(+) current and promotes spasticity after spinal cord injury.
Topics: Animals; Calpain; Dipeptides; Gene Expression Regulation; HEK293 Cells; Humans; Motor Neurons; NAV1. | 2016 |
Combining neuroprotective agents: effect of riluzole and magnesium in a rat model of thoracic spinal cord injury.
Topics: Animals; Drug Therapy, Combination; Female; Magnesium; Neuroprotective Agents; Rats; Rats, Wistar; R | 2016 |
Predicting Recruitment Feasibility for Acute Spinal Cord Injury Clinical Trials in Canada Using National Registry Data.
Topics: Adult; Aged; Canada; Databases, Factual; Feasibility Studies; Female; Forecasting; Humans; Male; Mid | 2017 |
Electrospun Fibers for Drug Delivery after Spinal Cord Injury and the Effects of Drug Incorporation on Fiber Properties.
Topics: Animals; Drug Delivery Systems; Humans; Microscopy, Electron, Scanning; Neurotrophin 3; Polyesters; | 2016 |
Effectiveness of riluzole in suppressing spasticity in the spinal cord injured rat.
Topics: Animals; Electromyography; Female; Muscle Spasticity; Neuroprotective Agents; Rats; Rats, Sprague-Da | 2009 |
Antinociceptive effect of riluzole in rats with neuropathic spinal cord injury pain.
Topics: Animals; Hyperalgesia; Injections, Intraperitoneal; Injections, Intraventricular; Injections, Spinal | 2011 |
Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury.
Topics: Action Potentials; Analysis of Variance; Animals; Calcimycin; Calcium; Calcium Ionophores; Capillari | 2012 |
A study of the potential neuroprotective effect of riluzole on locomotor networks of the neonatal rat spinal cord in vitro damaged by excitotoxicity.
Topics: Animals; Animals, Newborn; Cell Count; Cell Survival; Electric Stimulation; Electrophysiological Phe | 2012 |
The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord.
Topics: Animals; Arachidonate 5-Lipoxygenase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cas | 2013 |
Multicenter clinical research networks for traumatic spinal cord injury: a critical pathway to discovery.
Topics: Clinical Trials as Topic; Goals; Humans; Neuroprotective Agents; Riluzole; Spinal Cord Injuries | 2012 |
North American Clinical Trials Network for the Treatment of Spinal Cord Injury: goals and progress.
Topics: Clinical Trials as Topic; Databases, Factual; Goals; Humans; Neuroprotective Agents; Recovery of Fun | 2012 |
Delayed riluzole treatment is able to rescue injured rat spinal motoneurons.
Topics: Amidines; Analysis of Variance; Animals; Cell Count; Cell Survival; Choline O-Acetyltransferase; Dru | 2007 |
Riluzole promotes cell survival and neurite outgrowth in rat sensory neurones in vitro.
Topics: Analysis of Variance; Animals; Animals, Newborn; Cell Count; Cell Survival; Cells, Cultured; Disease | 2006 |
Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Lipid Peroxidation; Locomotion; Male; Mexiletine; | 2007 |
Rapid calpain I activation and cytoskeletal protein degradation following traumatic spinal cord injury: attenuation with riluzole pretreatment.
Topics: Animals; Calpain; Contusions; Cytoskeletal Proteins; Enzyme Activation; Excitatory Amino Acid Antago | 1997 |
Neuroprotective effects of riluzole in neurotrauma models: a review.
Topics: Animals; Brain Edema; Brain Injuries; Cognition; Evoked Potentials, Somatosensory; Memory; Neurologi | 1999 |
Riluzole improves measures of oxidative stress following traumatic spinal cord injury.
Topics: Animals; Female; Glutamic Acid; Mitochondria; Neuroprotective Agents; Neurotoxins; Oxidative Stress; | 2000 |
Riluzole and methylprednisolone combined treatment improves functional recovery in traumatic spinal cord injury.
Topics: Animals; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Gait Disorders, Neuro | 2000 |
Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole.
Topics: Animals; Axons; Behavior, Animal; Efferent Pathways; Female; Neuroprotective Agents; Rats; Rats, Wis | 2001 |